| 000 | 00881 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250515002154.0 | ||
| 264 | 0 | _c20070125 | |
| 008 | 200701s 0 0 eng d | ||
| 022 | _a1744-7631 | ||
| 024 | 7 |
_a10.1517/14728222.9.5.975 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKlebl, Bert M | |
| 245 | 0 | 0 |
_aSecond-generation kinase inhibitors. _h[electronic resource] |
| 260 |
_bExpert opinion on therapeutic targets _cOct 2005 |
||
| 300 |
_a975-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xchemistry |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 700 | 1 | _aMüller, Gerhard | |
| 773 | 0 |
_tExpert opinion on therapeutic targets _gvol. 9 _gno. 5 _gp. 975-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14728222.9.5.975 _zAvailable from publisher's website |
| 999 |
_c15816638 _d15816638 |
||